C97 Stock Overview
A molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Co-Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.20 |
| 52 Week High | US$8.24 |
| 52 Week Low | US$4.20 |
| Beta | -0.61 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 285.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| C97 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -2.0% |
| 1Y | n/a | -8.5% | 6.9% |
Return vs Industry: Insufficient data to determine how C97 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how C97 performed against the German Market.
Price Volatility
| C97 volatility | |
|---|---|
| C97 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C97 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine C97's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 101 | Dwight Egan | www.codiagnostics.com |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.
Co-Diagnostics, Inc. Fundamentals Summary
| C97 fundamental statistics | |
|---|---|
| Market cap | €119.33m |
| Earnings (TTM) | €27.87m |
| Revenue (TTM) | €77.84m |
4.3x
P/E Ratio1.5x
P/S RatioIs C97 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C97 income statement (TTM) | |
|---|---|
| Revenue | US$78.22m |
| Cost of Revenue | US$10.00m |
| Gross Profit | US$68.23m |
| Other Expenses | US$40.23m |
| Earnings | US$28.00m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
| Earnings per share (EPS) | 0.83 |
| Gross Margin | 87.22% |
| Net Profit Margin | 35.80% |
| Debt/Equity Ratio | 0% |
How did C97 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/09 01:33 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Co-Diagnostics, Inc. is covered by 2 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| James Sidoti | Sidoti & Company, LLC |